» Articles » PMID: 19853220

Identification of Pharmacoresistant Epilepsy

Overview
Journal Neurol Clin
Specialty Neurology
Date 2009 Oct 27
PMID 19853220
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

There is no single definition of pharmacoresistant (intractable, refractory) epilepsy. Prospective identification of pharmacoresistance is complicated by the variability of its appearance across different types of epilepsy and the variability of seizure control within a given patient over time. Failure of informative trials of two appropriate antiepileptic drugs has been recommended as a threshold that should trigger referral for evaluation at a comprehensive epilepsy center. Maximizing seizure control is imperative for reducing the risks and consequences of epilepsy, including the cognitive and psychiatric comorbidities and even sudden death.

Citing Articles

Identifying Postural Instability in Children with Cerebral Palsy Using a Predictive Model: A Longitudinal Multicenter Study.

Bertoncelli C, Bertoncelli D, Bagui S, Bagui S, Costantini S, Solla F Diagnostics (Basel). 2023; 13(12).

PMID: 37371021 PMC: 10297475. DOI: 10.3390/diagnostics13122126.


Prediction Model for Identifying Computational Phenotypes of Children with Cerebral Palsy Needing Neurotoxin Treatments.

Bertoncelli C, Latalski M, Bertoncelli D, Bagui S, Bagui S, Gautier D Toxins (Basel). 2023; 15(1).

PMID: 36668840 PMC: 9867395. DOI: 10.3390/toxins15010020.


Human cortical interneurons optimized for grafting specifically integrate, abort seizures, and display prolonged efficacy without over-inhibition.

Zhu Q, Mishra A, Park J, Liu D, Le D, Gonzalez S Neuron. 2023; 111(6):807-823.e7.

PMID: 36626901 PMC: 10023356. DOI: 10.1016/j.neuron.2022.12.014.


Prediction Model for Identifying Factors Associated with Epilepsy in Children with Cerebral Palsy.

Bertoncelli C, Dehan N, Bertoncelli D, Bagui S, Bagui S, Costantini S Children (Basel). 2022; 9(12).

PMID: 36553361 PMC: 9777044. DOI: 10.3390/children9121918.


Evaluation of the efficacy and tolerability of levetiracetam as add-on therapy in intractable epilepsy of children.

Razieh R, Shafiei A, Dehghani Firouzabadi F, Fathi A Iran J Child Neurol. 2022; 16(2):77-84.

PMID: 35497099 PMC: 9047840. DOI: 10.22037/ijcn.v15i4.29028.


References
1.
Jallon P, Loiseau P, Loiseau J . Newly diagnosed unprovoked epileptic seizures: presentation at diagnosis in CAROLE study. Coordination Active du Réseau Observatoire Longitudinal de l' Epilepsie. Epilepsia. 2001; 42(4):464-75. DOI: 10.1046/j.1528-1157.2001.31400.x. View

2.
Casetta I, Granieri E, Monetti V, Gilli G, Tola M, Paolino E . Early predictors of intractability in childhood epilepsy: a community-based case-control study in Copparo, Italy. Acta Neurol Scand. 1999; 99(6):329-33. DOI: 10.1111/j.1600-0404.1999.tb07360.x. View

3.
Berg A, Levy S, Novotny E, Shinnar S . Predictors of intractable epilepsy in childhood: a case-control study. Epilepsia. 1996; 37(1):24-30. DOI: 10.1111/j.1528-1157.1996.tb00507.x. View

4.
Klepper J, Leiendecker B . GLUT1 deficiency syndrome--2007 update. Dev Med Child Neurol. 2007; 49(9):707-16. DOI: 10.1111/j.1469-8749.2007.00707.x. View

5.
Berg A, Kelly M . Defining intractability: comparisons among published definitions. Epilepsia. 2006; 47(2):431-6. DOI: 10.1111/j.1528-1167.2006.00440.x. View